JP2010530380A5 - - Google Patents

Download PDF

Info

Publication number
JP2010530380A5
JP2010530380A5 JP2010512555A JP2010512555A JP2010530380A5 JP 2010530380 A5 JP2010530380 A5 JP 2010530380A5 JP 2010512555 A JP2010512555 A JP 2010512555A JP 2010512555 A JP2010512555 A JP 2010512555A JP 2010530380 A5 JP2010530380 A5 JP 2010530380A5
Authority
JP
Japan
Prior art keywords
phenyl
methyl
pyrrol
piperazin
ethane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010512555A
Other languages
English (en)
Japanese (ja)
Other versions
JP5371969B2 (ja
JP2010530380A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/004459 external-priority patent/WO2008155022A1/en
Publication of JP2010530380A publication Critical patent/JP2010530380A/ja
Publication of JP2010530380A5 publication Critical patent/JP2010530380A5/ja
Application granted granted Critical
Publication of JP5371969B2 publication Critical patent/JP5371969B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010512555A 2007-06-18 2008-06-04 P2y12拮抗薬としてのピロール誘導体 Expired - Fee Related JP5371969B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07290755 2007-06-18
EP07290755.3 2007-06-18
PCT/EP2008/004459 WO2008155022A1 (en) 2007-06-18 2008-06-04 Pyrrole derivatives as p2y12 antagonists

Publications (3)

Publication Number Publication Date
JP2010530380A JP2010530380A (ja) 2010-09-09
JP2010530380A5 true JP2010530380A5 (https=) 2011-07-07
JP5371969B2 JP5371969B2 (ja) 2013-12-18

Family

ID=39092503

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010512555A Expired - Fee Related JP5371969B2 (ja) 2007-06-18 2008-06-04 P2y12拮抗薬としてのピロール誘導体

Country Status (12)

Country Link
US (1) US7910576B2 (https=)
EP (1) EP2167487B1 (https=)
JP (1) JP5371969B2 (https=)
KR (1) KR20100020478A (https=)
CN (1) CN101679358B (https=)
AU (1) AU2008266515B2 (https=)
BR (1) BRPI0812912A2 (https=)
CA (1) CA2690243A1 (https=)
IL (1) IL202758A (https=)
MX (1) MX2009013431A (https=)
MY (1) MY148901A (https=)
WO (1) WO2008155022A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090073231A (ko) 2006-10-20 2009-07-02 노파르티스 아게 3-(1h-인돌-3-일)-4-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-피롤-2,5-디온의 결정 변체
WO2013033178A1 (en) 2011-08-30 2013-03-07 University Of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN121108187A (zh) 2019-04-03 2025-12-12 阿里戈斯治疗公司 吡咯化合物
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3458515A (en) * 1966-07-21 1969-07-29 American Home Prod Piperazine substituted pyrroles
US20020061892A1 (en) * 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
US6956040B2 (en) * 2001-07-16 2005-10-18 Ranbaxy Laboratories Limited Oxazolidinone piperazinyl derivatives as potential antimicrobials
OA12970A (en) 2002-12-11 2006-10-13 Schering Ag 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists.
WO2005009971A1 (ja) 2003-07-24 2005-02-03 Astellas Pharma Inc. キノロン誘導体又はその塩
US7273881B2 (en) * 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
CN1778801A (zh) * 2004-11-22 2006-05-31 中国农业科学院兰州畜牧与兽药研究所 喹诺酮7-((4-((z)-2-(2-氨基-4-噻唑基)-2-甲氧亚胺乙酰基)-1-哌嗪基)化合物及其制备方法
EP1836189A1 (en) * 2005-01-06 2007-09-26 AstraZeneca AB Novel pyridine compounds
JP2008094720A (ja) 2005-01-20 2008-04-24 Astellas Pharma Inc キノロン誘導体のプロドラッグ又はその塩
CA2603041A1 (en) * 2005-03-28 2006-10-05 Pharmacia & Upjohn Company Llc 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
KR101423483B1 (ko) * 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔4-(6-할로-7-치환된-2,4-디옥소-1,4-디히드로-2h-퀴나졸린-3-일)-페닐〕-5-클로로티오펜-2-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법
WO2007103456A2 (en) * 2006-03-06 2007-09-13 Trimeris, Inc. Piperazine and piperidine biaryl derivatives

Similar Documents

Publication Publication Date Title
JP2010530380A5 (https=)
JP2011507915A5 (https=)
AU2005230881B9 (en) Histamine H3 receptor agents, preparation and therapeutic uses
TWI326681B (en) 4,4,5,5 tetrasubstituted imidazolines
RU2007143073A (ru) Азольные соединения с нейтротерапевтической активностью
US6555537B2 (en) Piperazine derivatives and their use as anti-inflammatory agents
JP5244091B2 (ja) Ep4受容体アンタゴニストとしてのインドールアミド誘導体
RU2010142937A (ru) НОВЫЕ ПРОИЗВОДНЫЕ ПИПЕРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ СТЕАРОИЛ-КоА ДЕСАТУРАЗЫ
KR20080080410A (ko) 이미다졸린 유도체의 치환된 2-이미다졸의 용도
DE602004006431D1 (de) Derivate von n-äheteroaryl(piperidin-2-yl)methylübenzamid, verfahren zu deren herstellung und deren anwendung in therapeutika
NZ591024A (en) Substituted pyrrolidine-2-carboxamides
JP2010539152A5 (https=)
HRP20170338T1 (hr) Fluorometil-supstituirani pirolkarboksamidi
HRP20161641T1 (hr) Antagonisti piperidinon karboksamid azaindan cgrp receptora
JP2018536653A5 (https=)
JP2010533722A5 (https=)
JP2004508304A5 (https=)
CN1496981A (zh) 环胺衍生物及其作为药物的用途
JP2004508356A5 (https=)
RU2009132108A (ru) Иммунодепрессантные соединения и композиции
JP2009535426A5 (https=)
EA012703B1 (ru) Производные пиримидина и их применение в качестве модуляторов cb2
PE20110570A1 (es) Heterociclos biciclicos sustituidos
RU2463294C2 (ru) 1,3-дизамещенные 4-метил-1н-пиррол-2-карбоксамиды и их применение для изготовления лекарственных средств
MY150448A (en) 1- [2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition